Karyopharm Therapeutics reported $-42759000 in EBITDA for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Abbott ABT:US $ 2985M 750M
Amgen AMGN:US $ 3004M 337M
AstraZeneca AZN:LN 3562M 625M
Astrazeneca AZN:US $ 3562M 625M
Avrobio Inc AVRO:US $ -27420000 1.6M
Bristol Myers Squibb BMY:US $ 5780M 8M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Enanta Pharmaceuticals ENTA:US $ -31.82M 1.2M
Epizyme EPZM:US $ -28.52M 21.1M
GlaxoSmithKline GSK:LN 2447M 673M
Johnson & Johnson JNJ:US $ 8036M 1273M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Macrogenics MGNX:US $ -38931000 24.79M
Mirati Therapeutics MRTX:US $ -176.51M 7.08M
Nektar Therapeutics NKTR:US $ -44.27M 67.08M
Novartis NOVN:VX SF 4660M 108M
Novartis NVS:US $ 4660M 108M
Pfizer PFE:US $ 12921M 1739M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Sangamo Biosciences SGMO:US $ -42.85M 0.42M
Takeda 4502:JP Y 308798M 158143M
Ultragenyx Pharmaceutical RARE:US $ -137.11M 4.57M
Xencor XNCR:US $ -25.78M 54.42M
YTE INCY:US $ 276.8M 132.69M